BRD7 and melanoma: Since these ECM genes which have specific pharmacological inhibitors are significantly overexpressed in patient-derived melanoma samples compared to normal skin samples and few of them are also significantly co-expressed with TP-472 target epigenetic regulator BRD7, they can be targeted either alone or in combination with TP-472, to enhance the effectiveness and durability of melanoma therapy